Pharmaceuticals Not Likely To Be A Target Of Republicans In Coming Congress, Hill Watchers Say
This article was originally published in The Pink Sheet Daily
Some issues - such as drug importation or rebates for Medicare/Medicaid dual eligibles - could surface. GOP could make "surgical strikes" on health reform law, including the Independent Payment Advisory Board, if overall repeal of reform law fails.
You may also be interested in...
The co-chairs of the bipartisan National Commission on Fiscal Responsibility and Reform issued a cost-savings proposal for the government, including Medicare, on Nov. 10, but it will need approval by 14 of 18 members before going to the president.
The anti-government intervention sentiment coming to Congress in January with the newly elected Republicans presents a tactical challenge to lobbying efforts by the Pharmaceutical Research and Manufacturers of America.
The $80 billion deal the Rx industry struck as part of health care reform lives to see another day as drug importation fails on the Senate floor.